Novo Nordisk (NVO) has released an update.
Novo Nordisk, a global healthcare leader based in Denmark, has disclosed the sale of 9,000 shares by Executive Vice President Martin Holst Lange, as per market abuse regulations. The shares were sold on Nasdaq Copenhagen for a total of DKK 8,239,500. The company is renowned for its commitment to combating serious chronic diseases and has a significant global presence with around 63,400 employees and products available in approximately 170 countries.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
